Journal
BIOMEDICINES
Volume 9, Issue 9, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9091278
Keywords
I kappa B alpha; SUMOylation; NF-kappa B; polycomb repression complex (PRC) 2; cancer
Categories
Funding
- Instituto de Salud Carlos III/FEDER [PI19/00013]
- Generalitat de Catalunya [2017SGR135]
Ask authors/readers for more resources
I kappa B alpha is known for inhibiting the NF-kappa B signaling pathway, but alterations found in cancer may be associated with either NF-kappa B-dependent or NF-kappa B-independent activities of the protein.
I kappa B alpha is considered to play an almost exclusive role as inhibitor of the NF-kappa B signaling pathway. However, previous results have demonstrated that SUMOylation imposes a distinct subcellular distribution, regulation, NF-kappa B-binding affinity and function to the I kappa B alpha protein. In this review we discuss the main alterations of I kappa B alpha found in cancer and whether they are (most likely) associated with NF-kappa B-dependent or NF-kappa B-independent (moonlighting) activities of the protein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available